| Document |
Document Title |
|
WO/2018/210297A1 |
Disclosed are an intermediate of Eribulin and a preparation method therefor. In particular, disclosed are compounds as represented by formula II, formula III and formula V and a preparation method therefor. Ar is C1-10 alkyl substituted,...
|
|
WO/2018/200471A1 |
The present invention is directed to reactor systems and processes for producing organic acids through thermolysis of polylactones. In preferred embodiments, the reactor systems and processes are capable of introducing at least one epoxi...
|
|
WO/2018/192083A1 |
Methods and compounds for preventing and /or treating Zika virus(ZIKA) infection. And methods to screen for compound to prevent or treat Zika virus infection.
|
|
WO/2018/195155A1 |
The present embodiments related to substituted heterocyclic derivative therapeutic compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-m...
|
|
WO/2018/188643A1 |
Relating to an opioid receptor agonist (1S,4S)-4-ethoxy-N-(2-((R)-9-(pyridin-2-yl)-6-oxaspiro[4.5]d
eca-9-yl)ethyl)-1,2,3,4-tetrahydronaphthalen-1-amine fumarate salt, a fumarate salt I crystal form thereof, and a preparation method and ...
|
|
WO/2018/188795A1 |
The present invention relates to sulfonamide-, sulfinamide- or sulfonimidamide containing compounds which bind to the liver X receptor (LXRa and/or LXRß) and act preferably as inverse agonists of LXR.
|
|
WO/2018/179998A1 |
The purpose of the present invention is to provide: a novel procyanidin having an excellent polysaccharide digestion inhibition effect; and a method for producing the same. Provided is a procyanidin characterized by having a basic skelet...
|
|
WO/2018/169055A1 |
It is known that foods containing a carbohydrate, e.g., starch, in a large amount generate acrylamide upon heating at high temperatures. Some documents state that acrylamide is formed by the Maillard reaction of an amino acid, e.g., aspa...
|
|
WO/2018/167270A1 |
Anticancer compounds of general formula (I), wherein R1 to R4 take various meanings, for use in the treatment of cancer. A novel Labrenziasp. strain named PHM005 with Accession Deposit Number CECT-9225, a method of producing compounds of...
|
|
WO/2018/163194A1 |
The present invention relates to a process for the preparation of D-glucitol, 1,5- anhydro-1-C-[4-chloro-3-[[ 4-[[(3S)-tetrahydro-3-furanyl)oxy )phenyl] methyl]phenyl]-, (IS) formula-1.
|
|
WO/2018/159964A1 |
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, it is possible to pro...
|
|
WO/2018/155340A1 |
The purpose of the present invention is to provide a liquid crystalline compound; a liquid crystal composition containing the compound; and a liquid crystal display element including the composition, the liquid crystalline compound satis...
|
|
WO/2018/154493A1 |
The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compo...
|
|
WO/2018/153507A1 |
Compounds of formula (I), wherein R', R'', R, X, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
|
|
WO/2018/149857A1 |
The present invention relates to novel 2-oxo-2H-chromen compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositio...
|
|
WO/2018/150421A1 |
The invention provides efficient cyclization processes of hydroxyalkenoic acids and products produced therefrom. The following reactions are claimed: Formula (I), (II), (V) and (VI).
|
|
WO/2018/149991A1 |
The present invention relates to particular sulfonamide derivatives, the pharmaceutically acceptable addition salts thereof, the hydrates thereof and/or the solvates thereof, and also the use thereof as inverse agonists of retinoid-relat...
|
|
WO/2018/146471A1 |
There is provided compounds of formula I (I) or pharmaceutically-acceptable salts thereof, wherein L, R1, R2, R3 and X have meanings5 provided in the description, which compounds are useful in the treatment of cancers.
|
|
WO/2018/141706A1 |
The invention relates to propellane compounds according to defined formula, to the use of said compounds in electronic devices, and to electronic devices containing one or more of the known propellane compounds. The invention also relate...
|
|
WO/2018/138029A1 |
The present invention relates to compounds of general formula (I), wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate...
|
|
WO/2018/133795A1 |
An inhibitor of a wild type and Y641F mutant of human histone methyltransferase EZH2. Particularly, the inhibitor is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The inhibitor can be used to treat ...
|
|
WO/2018/130625A1 |
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable ...
|
|
WO/2018/054989A9 |
The invention relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kin...
|
|
WO/2018/122232A1 |
Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.
|
|
WO/2018/116185A1 |
The invention discloses compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, A, R19, R20, and R21 are as defined herein. The present invention relates to deuterated compounds and their ...
|
|
WO/2018/113201A1 |
A compound as represented by formula (I), or a stereoisomer, a tautomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof, a preparation method therefor, a pharmaceutical composition comprising ...
|
|
WO/2018/112331A1 |
The present invention provides lifitegrast formulations useful for the treatment of immune-related diseases of the ocular surface. The formulations and methods provided herein are particularly useful for treatment of ocular anterior segm...
|
|
WO/2018/104295A1 |
Disclosed are sulfonamide analogues of galiellactone of formula (I) as STAT3-inhibitors for use in the treatment of a STAT3 signaling related disorder, e.g. solid cancers, hematological cancers, benign tumors, hyperproliferative diseases...
|
|
WO/2018/099431A1 |
Disclosed is a pyrene organic compound having the following structural formula. The pyrene organic compound has better charge transfer performance and luminous efficiency, and also has better thermal stability. Therefore, by providing an...
|
|
WO/2018/100834A1 |
Provided is a composition that has excellent near-infrared ray absorption stability and is useful for an optical film. The composition includes at least two of the compounds represented by general formula 2 or general formula 5.
|
|
WO/2018/098831A1 |
Provided are a biomass-based epoxy resin and method for preparation thereof; under conditions of N,N-dimethylformamide as a catalyst, 2,5-furandicarboxylic acid and thionyl chloride are acylated to obtain 2,5-furan diformyl chloride; the...
|
|
WO/2018/089330A2 |
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseas...
|
|
WO/2018/089406A1 |
There are described RORɣ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical composi...
|
|
WO/2018/084266A1 |
Herein disclosed are compounds, compositions, kits, and methods of treating cancers using 7-azaindolyl furanone/thiophene derivatives. These derivatives inhibit serine-threonine kinase Cdc7, a recognized anticancer target affecting DNA r...
|
|
WO/2018/078005A1 |
The present invention relates to amido-substituted cyclohexane compounds of general formula (I) : in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful...
|
|
WO/2018/067382A1 |
Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially ...
|
|
WO/2017/102784A9 |
The present specification provides a compound of formula (I): (I) or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an RORγ and/or RORγt mediat...
|
|
WO/2018/064119A1 |
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2018/062778A1 |
The present disclosure relates to an organic electroluminescent device comprising a first electrode, a second electrode facing the first electrode, a light-emitting layer between the first electrode and the second electrode, and an elect...
|
|
WO/2018/055402A1 |
The present invention relates to compounds of formula (I), and salts and solvates thereof, that function as inhibitors of cell division cycle 7 (Cdc7) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, and n are each as defined her...
|
|
WO/2018/053588A1 |
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.
|
|
WO/2018/057973A1 |
Disclosed are compounds of Formula I (a) or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, R5, R6, R7, G1, G2 and Ring A are as described in any of the embodiments describ...
|
|
WO/2018/050477A1 |
The present invention relates to relates to novel strigolactone derivatives of formula (I), to processes for preparing these derivatives including intermediate compounds, to seeds comprising these derivatives, to plant growth regulator o...
|
|
WO/2018/033088A1 |
Provided are a five-membered ring substituted compound having xanthone as the core and applications thereof. The compound has xanthone as the parent core and is connected to an aromatic heterocyclic group, thereby breaking molecular symm...
|
|
WO/2018/033085A1 |
Disclosed are a compound using anthrone as a core and applications thereof in an organic electroluminescent component. The compound uses anthrone as a parent core, which is connected to an aromatic heterocyclic group, so that the molecul...
|
|
WO/2018/031877A1 |
Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to...
|
|
WO/2018/024017A1 |
The present invention relates to a preparation method for 6-fluoro-2-(epoxy-2-yl)chroman. The preparation method comprises the following steps: (1) if a compound as represented by formula (II) is in an R form, subjecting a compound as re...
|
|
WO/2018/024907A1 |
The present invention relates to novel piperidine derivatives having better cell growth inhibitory activities toward cancer cell cultures and, more particularly, PANC-1 cancer cell cultures than FK866. Accordingly, the present invention ...
|
|
WO/2018/021890A1 |
The present invention relates to a novel cromenone derivative compound having heat shock protein 27 (HSP27) inhibitory activity. The composition, a pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the s...
|
|
WO/2018/015292A1 |
The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cance...
|
